Servier Acquires Day One Biopharmaceuticals in $2.5 Billion Oncology Deal
French pharmaceutical firm Servier will acquire Day One Biopharmaceuticals for $2.5 billion, gaining the pediatric glioma treatment Ojemda. The deal offers a 68% premium to Day One's recent closing price.
Markets
